Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy

Journal of Immunotherapy

Volumn 32, Issue 6, 2009, Pages 638-654

  Hayden, Hubert ^a   Friedl, Josef ^a   Dettke, Markus ^a   Sachet, Monika ^a   Hassler, Michaela ^a   Dubsky, Peter ^a   Bachleitner Hofmann, Thomas ^a   Gnant, Michael ^a   Stift, Anton ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cryopreservation; Dendritic cells; Dendritic cell culture; Immunotherapy; Monocytes

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12P70;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CRYOPRESERVATION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CANCER VACCINES; CELL LINE, TUMOR; CRYOPRESERVATION; DENDRITIC CELLS; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; MONOCYTES; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 67651146819     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a5bc13     Document Type: Article

References (61)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182:389-400.
3. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
4. Fricke I, Gabrilovich DI. Dendritic cells and tumor micro-environment: a dangerous liaison. Immunol Invest. 2006;35: 459-483.
5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
6. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117: 1195-1203.
7. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297-1302.
8. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol. 1996;156:2918-2926.
9. Kim JH, Lee Y, Bae YS, et al. Phase I/II study of immuno-therapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol. 2007;125:257-267.
10. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
11. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
12. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
13. Tamir A, Basagila E, Kagahzian A, et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother. 2007;56:2003-2016.
14. Hirschowitz EA, Foody T, Kryscio R, et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004;22:2808-2815.
15. Stift A, Sachet M, Yagubian R, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res. 2004;10: 2944-2953.
16. Stift A, Friedl J, Dubsky P, et al. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol. 2003;22:651-656.
17. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol. 2003;21:135-142.
18. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007;56: 1513-1537.
19. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother. 2004;53:275-306.
20. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest. 2002;110:289-294.
21. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
22. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus inter-leukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
23. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996;59:208-218.
24. Dubsky P, Hayden H, Sachet M, et al. Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. Cancer Immunol Immunother. 2008; 57:859-870.
25. Bachleitner-Hofmann T, Strohschneider M, Krieger P, et al. Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:4571-4577.
26. Elkord E, Williams PE, Kynaston H, et al. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology. 2005;114:204-212.
27. Breckpot K, Corthals J, Heirman C, et al. Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. Hum Gene Ther. 2004;15:562-573.
28. Rouard H, Leon A, De Reys S, et al. A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. Transfusion. 2003;43: 481-487.
29. Berger TG, Strasser E, Smith R, et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods. 2005;298: 61-72.
30. Lewalle P, Rouas R, Lehmann F, et al. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Methods. 2000;240:69-78.
31. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.
32. Feuerstein B, Berger TG, Maczek C, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods. 2000;245:15-29.
33. Hori S, Heike Y, Takei M, et al. Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes. J Immunother. 2004;27:27-35.
34. Nagayama H, Sato K, Morishita M, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose inter-leukin-2. Melanoma Res. 2003;13:521-530.
35. Kavanagh B, Ko A, Venook A, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007;30:762-772.
36. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279-1288.
37. Escobar A, Lopez M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of inter-leukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005;142:555-568.
38. Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int. 2004;94:412-418.
39. Buchta C, Macher M, Bieglmayer C, et al. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion. 2003;43:1615-1621.
40. Chen Y, Hoecker P, Zeng J, et al. Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: clinical study. J Clin Apheresis. 2008;23:157-162.
41. Kalinski P, Hilkens CM, Wierenga EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999;20:561-567.
42. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655-2661.
43. + regulatory T cells from human CD4+CD25-cells. Proc Natl Acad Sci USA. 2005;102:4103-4108.
44. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000; 192:1213-1222.
45. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005;28:129-135.
46. Huang J, Wang Y, Guo J, et al. Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression. Clin Immunol. 2007;123:298-310.
47. Bauer C, Bauernfeind F, Sterzik A, et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut. 2007;56:1275-1282.
48. Lin YL, Liang YC, Chiang BL. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J Leukoc Biol. 2007;82:1473-1480.
49. Messmer D, Hatsukari I, Hitosugi N, et al. Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human dendritic cells and enhances T cell activation. Mol Med. 2006;12:284-290.
50. Venkataraman M. Effects of cryopreservation on immune responses. X. Decrease in interleukin-12 production by frozen human peripheral blood mononuclear cells is mediated by the endogenously hypersecreted interleukin-10. Cryobiology. 1996; 33:581-588.
51. Venkataraman M. Effects of cryopreservation on immune responses: IX. Stimulus-mediated dichotomy in IL-10 production by frozen human peripheral blood mononuclear cells. J Hematother. 1996;5:301-308.
52. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999;162: 3231-3236.
53. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
54. Macgregor JN, Li Q, Chang AE, et al. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immuno-therapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res. 2006;66:4913-4921.
55. Baroja A, de la Hoz C, Alvarez A, et al. Polyploidization and exit from cell cycle as mechanisms of cultured melanoma cell resistance to methotrexate. Life Sci. 1998;62:2275-2282.
56. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-284.
57. Sundaram M, Guernsey DL, Rajaraman MM, et al. Neosis: a novel type of cell division in cancer. Cancer Biol Ther. 2004; 3:207-218.
58. Erenpreisa JA, Cragg MS, Fringes B, et al. Release of mitotic descendants by giant cells from irradiated Burkitt's lymphoma cell line. Cell Biol Int. 2000;24:635-648.
59. Ogino A, Kitao H, Hirano S, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007;67:7807-7814.
60. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55:4438-4445.
61. Chen MW, Vacherot F, De La Taille A, et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene. 2002; 21:7861-7871.